Our work suggests MeCP2 uses a different molecular mechanism to drive tumor progression in CRC: MeCP2 binds to SPI1 and aids its recruitment to the ZEB1 promoter, which in turn, affects ZEB1 expression at the transcription level. The gene discussed is ZEB1; the disease is neoplasm.